Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...
The updated 2025-2026 COVID-19 vaccines are now widely available, but with some new limitations. Who can get the shot this ...
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...
Amid confusion over this year's updated COVID-19 vaccines, we explain what's different this year and who experts say should ...
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...
Americans headed to pharmacies for COVID-19 vaccines are running into roadblocks and confusion due to new U.S. guidance that ...
Moderna's Phase 1/2 study shows mRNA-4359 plus pembrolizumab yields 24% response rate and 60% disease control in resistant ...
Trump's physician, Sean Barbabella, shared news of the president's COVID vaccination in a letter to White House press ...
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback